Treatment of deep vein thrombosis using low-molecular-weight heparins

American Journal of Managed Care

Volumn 7, Issue 17 SUPPL., 2001, Pages

  Groce III, J B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; INFUSION FLUID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG USE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HOME CARE; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY FAILURE; MEDICAL CARE; META ANALYSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; OBESITY; OUTPATIENT CARE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AMBULATORY CARE; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; HALF-LIFE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINES; UNITED STATES; VENOUS THROMBOSIS;

EID: 0035198865     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Register (ICOPER)
2. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials
3. Antithrombotic therapy for venous thromboembolic disease
4. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
5. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
6. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
7. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group
8. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
9. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
10. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
11. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
12. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin
13. Cost for inpatient care of venous thrombosis: A trial of enoxaparin vs standard heparin
14. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group
15. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis
16. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
17. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
18. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
19. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency